Beam Therapeutics Secures FDA Accelerated Approval Pathway for BEAM-302 and Plans BLA Submission for Risto-cel by Year-End 2026
核心洞察
Beam Therapeutics has reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302 in alpha-1 antitrypsin deficiency (搜索) based on biomarker endpoints evaluated over 12 months.
The company expects to submit a Biologics Licensing Application for risto-cel (搜索), its sickle cell disease (搜索) therapy, as early as year-end 2026 following completion of manufacturing for all doses.
Beam ended 2025 with an estimated $1.25 billion in cash and projects an operating runway extending into 2029 to support anticipated product launches and pivotal development programs.
Beam Therapeutics announced significant regulatory progress for its precision genetic medicine platform, securing FDA alignment on an accelerated approval pathway for its lead alpha-1 antitrypsin deficiency (搜索) therapy while advancing toward a potential market launch of its sickle cell disease (搜索) treatment by late 2026.
The Cambridge-based biotechnology company has reached alignment with the U.S. Food and Drug Administration on a potential accelerated approval pathway for BEAM-302 based on AAT (搜索) biomarkers evaluated over 12 months. BEAM-302 is designed as a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (搜索) that addresses the underlying pathophysiology of both liver and lung disease.
Breakthrough Clinical Results for BEAM-302
In an ongoing open-label Phase 1/2 clinical trial, treatment with BEAM-302 demonstrated the first-ever clinical in vivo genetic correction of a disease-causing mutation and established clinical proof of concept in AATD. To date, more than 25 AATD patients with lung and/or liver disease have been treated in the dose-exploration portions of the trial.
To support a future BLA submission, the company anticipates enrolling approximately 50 additional patients to be treated with the selected optimal biologic dose of BEAM-302 in an expansion of the ongoing Phase 1/2 study. BEAM-302 has also been accepted into the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program aimed at facilitating CMC development of products with expedited clinical development timeframes.
Beam expects to report updated data from the Phase 1/2 trial and next steps for pivotal development by the end of the first quarter of 2026.
Risto-cel Advances Toward Commercial Launch
Ristoglogene autogetemcel (risto-cel (搜索), formerly known as BEAM-101) represents an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (搜索). The most recent data from the ongoing BEACON Phase 1/2 clinical trial presented at the 67th American Society of Hematology Annual Meeting and Exposition continue to show evidence of risto-cel's differentiated treatment profile.
Risto-cel (搜索) has demonstrated a deeper resolution of SCD markers and reduced time in the hospital driven by a median of one cell collection cycle, rapid engraftment, and low number of neutropenic days. The therapy's predictable, robust manufacturing process led to fewer mobilizations and rapid delivery from cell collection to dose, potentially improving patient experience as well as treatment center capacity.
The adult and adolescent cohorts of the BEACON trial were fully enrolled in mid-2025, and manufacturing of all doses was completed as of December 2025. Beam completed interactions with the FDA on the anticipated BLA package for risto-cel (搜索), which is expected to align with regulatory precedent set by previously approved SCD gene therapies.
Expanding Pipeline and Platform Development
Beam is building a platform approach for single-course, precision gene editing therapies for liver-targeted genetic diseases by delivering base editors through intravenous infusion of lipid-nanoparticles, a clinically validated technology for delivery of nucleic acid payloads to the liver.
BEAM-301 aims to correct the most common disease-causing mutation, R83C, in patients with glycogen storage disease type Ia (搜索). BEAM-301 has the potential to normalize blood glucose in these patients without continuous supplementation and improve key metabolic parameters. The therapy is currently being evaluated in an open-label Phase 1/2 dose-exploration trial, with dosing complete in the first cohort and enrollment initiated in the second cohort.
The company expects to disclose the next clinical program for its liver-targeted genetic disease franchise in the first half of 2026.
Strong Financial Position Supports Development Timeline
Beam estimates that it had $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This estimate is inclusive of the $255.1 million in closing cash consideration received from the acquisition of Orbital Therapeutics (搜索) by Bristol-Myers Squibb (搜索). The company has the right to receive up to approximately $26.3 million in additional cash consideration upon the release of certain escrows from the transaction.
Beam now expects that its estimated cash position will enable the company to cover its anticipated operating expenses and capital expenditure requirements into 2029, funding the company through the anticipated launch of risto-cel (搜索) in SCD and execution of the BEAM-302 pivotal development plan in AATD.
"Over the past year, we have continued to demonstrate the power and consistency of our base editing platform as we work to redefine what is possible in genetic medicine," said John Evans, chief executive officer of Beam Therapeutics. "Our approach is rooted in precision and predictability – designing one-time treatments to reverse genetic disease, executing against our portfolio priorities with discipline, and generating differentiated clinical data that compound across programs."